Powder: -20°C for 3 years | In solvent: -80°C for 1 year
IRAK4-IN-20 是一种有效的、具有口服活性的 IRAK4 抑制剂( IC50 : 3.55 nM)。 IRAK4-IN-20 ,具有抗缓解炎症、抗肿瘤和抗癌作用,常用于治疗急性呼吸窘迫综合征 (ARDS) 。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,290 | 现货 | ||
5 mg | ¥ 2,990 | 现货 | ||
10 mg | ¥ 4,390 | 现货 | ||
25 mg | ¥ 6,910 | 现货 | ||
50 mg | ¥ 9,480 | 现货 | ||
100 mg | ¥ 12,800 | 现货 | ||
500 mg | ¥ 25,600 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 3,290 | 现货 |
产品描述 | IRAK4-IN-20 is a potent and orally active IRAK4 inhibitor (IC50:3.55 nM). IRAK4-IN-20, which has anti-inflammatory, antitumor and anticancer effects, is often used to treat acute respiratory distress syndrome (ARDS). |
靶点活性 | IRAK4:3.55 nM |
体外活性 | IRAK4-IN-20 (Compound BAY-1834845) (500 nM, 20 h) decreases inflammatory cytokines secretion effectively in an in vitro treatment of LPS stimulated human peripheral blood mononuclear cells (PBMC) [1]. |
体内活性 | IRAK4-IN-20 (Compound BAY-1834845) (150 mg/kg; p.o.; once or twice) effectively prevents acute respiratory distress syndrome in mice [1]. Animal Model: Female Balb/c mice (aged 6–7 weeks), LPS-induced ARDS mouse model [1] Dosage: 150 mg/kg Administration: Oral administration, 30 min before LPS modeling or twice 4 h and 12 h after LPS modeling Result: Remarkably decreased inflammatory cells infiltrating lung tissue and neutrophil count in BALF. Effectively reduced the numbers of total T cells, monocyte, and macrophages. Largely preserved the signatures of na ve lymphocytes and stromal cells such as endothelial cells, chondrocytes, and smooth muscle cells. Regulated inflammation and innate immunity genes more efficiently than Dexamethasone. |
别名 | BAY-1834845 |
分子量 | 450.45 |
分子式 | C22H25F3N4O3 |
CAS No. | 1931994-80-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25 mg/mL (55.5 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.22 mL | 11.1 mL | 22.2 mL | 55.5001 mL |
5 mM | 0.444 mL | 2.22 mL | 4.44 mL | 11.1 mL | |
10 mM | 0.222 mL | 1.11 mL | 2.22 mL | 5.55 mL | |
20 mM | 0.111 mL | 0.555 mL | 1.11 mL | 2.775 mL | |
50 mM | 0.0444 mL | 0.222 mL | 0.444 mL | 1.11 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
IRAK4-IN-20 1931994-80-7 Immunology/Inflammation NF-Κb IRAK BAY 1834845 BAY-1834845 BAY1834845 Inhibitor inhibitor inhibit